The respiratory syncitial virus and its role in acute bronchiolitis

European Journal of Pediatrics

Volumn 151, Issue 9, 1992, Pages 638-651

  Everard, M L ^a   Milner, A D ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; RIBAVIRIN; THROMBOSPONDIN; VIRUS ANTIBODY; VIRUS VACCINE; ALPHA INTERFERON; GLYCOPROTEIN; IMMUNOGLOBULIN;

ACUTE DISEASE; ANIMAL; BRONCHIOLITIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MONOCYTE; NEUTROPHIL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS INFECTION; THROMBOCYTE; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS INFECTION;

ACUTE DISEASE; ANIMAL; ANTIBODIES, VIRAL; BLOOD PLATELETS; BRONCHIOLITIS, VIRAL; HUMAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MONOCYTES; NEUTROPHILS; PLATELET MEMBRANE GLYCOPROTEINS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIROVIRUS INFECTIONS; RIBAVIRIN; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; THROMBOSPONDINS; VIRAL VACCINES;

EID: 0026612225     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/BF01957564     Document Type: Review

References (209)

1. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections
2. Pathological changes in virus infections of the lower respiratory tract in children
3. Serum complement in acute bronchiolitis
4. Antigenic characterisation of respiratory syncitial virus strains with monoclonal antibodies
5. Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncitial virus
6. Ribavirin aerosol for acute bronchiolitis
7. Parenteral administration of live respiratory syncitial virus vaccine: results of a field trial
8. Interleukin-1 inhibitor masks high interleukin-1 production in acquired immunodeficiency syndrom (AIDS)
9. Epidemiology of respiratory syncitial virus infections in Washington DC III. Composite analysis of eleven consecutive yearly epidemics
10. Respiratory syncitial virus in early infancy
11. Apnoea associated with respiratory syncitial virus infection in young infants
12. Deficiency of immune IFN production by leukocytes of normal newborns
13. Virus specific IgE and IgG4 antibodies in serum of children infected with respiratory syncitial virus
14. Regulation of TNF and IL1 secretion in human mononuclear phagocytes
15. Cytotoxic T cells clear virus but augment living pathology in mice infected with respiratory syncitial virus
16. Respiratory virus infections and aeroallergens in acute bronchial asthma
17. Acute bronchiolitis: predisposing factors and characterisation of infants at risk
18. Influence of immunological factors in respiratory syncitial virus disease of the lower respiratory tract
19. An enzyme linked immunoabsorbent assay (ELISA) for detection of respiratory syncitial virus in human nasal secretions
20. Development of cell mediated cytotoxic immunity to respiratory syncitial virus in human infants following naturally acquired infection
21. Interferon production by human mononuclear leukocytes. Differences between respiratory syncitial virus and influenza viruses
22. Comparison of three rapid diagnostic techniques for detection of respiratory syncytial virus from nasal wash specimens
23. Respiratory syncitial virus related apnoea in infants
24. Ribavirin therapy of respiratory syncytial virus
25. A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncitial virus
26. Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic
27. Immunoglobulins in tracheo-bronchial secretion with special reference to IgE
28. Respiratory syncitial virus infection of human mononuclear leucocytes in-vitro and in-vivo
29. Lung function and bronchial responsiveness in children who had infantile bronchiolitis
30. Complement activation by respiratory syncitial virus infected cells
31. Resistance to human respiratory syncitial virus infection induced by cotton rats with a recombinant vaccinia virus expressing the RSV G. glycoprotein
32. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection
33. Precautions in the use of ribavirin at the Children's Hospital
34. Neutrophils and antiviral defense
35. Activation of oxidative and arachidonic acid metabolism in neutrophiles by respiratory syncitial virus antibody complexes: possible role in disease
36. Activation and mucosal Migration of polymorphoneuclear leukocytes during respiratory syncitial virus infection
37. Phagocytic cell-derived inflammatory mediators and lung disease
38. Cellular and humoral immunity in recurrent respiratory syncitial virus infections
39. Ribavirin: a clinical overview
40. Epidemic infection caused by RSV in institutionalised young adults
41. Cellular response to respiratory viruses with particular reference to children with disorders of cell mediated immunity
42. Clinical observations on mechanical ventilation for respiratory failure in bronchiolitis
43. Acute lower respiratory illness in elderly patients with respiratory syncitial virus infection
44. Respiratory virus immunisation
45. The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection
46. How etiological, pathological and clinical diagnoses can be made in a correlated fashion
47. Application of immunofluoresent antibody technique in rapid diagnosis of respiratory syncitial virus infection
48. Viruses, bacteria and respiratory disease in children
49. Speculation on pathogenesis in death from respiratory syncitial virus infections
50. Interferon and respiratory syncitial virus
51. Virus cross infection in paediatric wards
52. Prostaglandin and thromboxane concentrations in plasma and lung lavage fluids during sequential infection of vaccinated and non-vaccinated calves with bovine respiratory syncitial virus
53. In-vitro enhancement of respiratory syncitial virus infection of U937 cells by human sera
54. Risk of respiratory syncitial virus infection for infants from low income families in relationship to age, sex, ethnic group and maternal antibody level
55. Risk of primary infection and re-infection with respiratory syncitial virus
56. Duration of hospitalisation in previously well infants with respiratory syncitial virus infection
57. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children
58. Modes of transmission of respiratory syncytial virus
59. Nosocomial respiratory syncytial virus infections
60. Respiratory syncitial virus infections within families
61. Respiratory syncytial virus: infections in infants: quantitation and duration of shedding
62. Interferon production in children with respiratory syncitial, influenza and parainfluenza virus infections
63. Control of nosocomial respiratory syncytial viral infections
64. Respiratory syncitial virus infection in adults
65. Clinical physiological manifestions of bronchiolitis and pneumonia
66. Neonatal respiratory syncitial virus infections
67. Interferon production in adults with respiratory syncitial viral infection
68. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study
69. Long term prospective study in children after respiratory syncitial virus infection
70. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease
71. Respiratory syncitial virus infection in children with compromised immune function
72. The risk of secondary bacterial infection in infants hospitalised with respiratory syncitial virus infection
73. Studies of passive immunotherapy for infections of respiratory syncitial virus in the respiratory tract of a primate model
74. Intravenous immunoglobulin treatment of respiratory syncitial virus infections in infants and young children
75. The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice
76. Respiratory syncitial virus infections, reinfections and immunity
77. Appearance of a soluable form of the G protein of respiratory syncitial virus in fluids of infected cells
78. Further characterisation of the soluble form of the G glycoprotein of respiratory syncitial virus
79. Concurrent circulation of antigenically distinct strains of respiratory syncitial during community outbreaks
80. Bronchiolitis (letter)
81. Respiratory problems 2 years after acute bronchiolitis in infancy
82. Ineffectiveness of ipratropium bromide in acute bronchiolitis
83. Age as a factor in the distribution of lower airway conductance and in the pathologic anatomy of obstructive lung disease
84. Detection by Elisa of IgG subclass-specific antibodies in primary respiratory syncitial virus infections
85. Detection of RS- virus IgG subclass specific antibodies: variations according to age in infants and small children and diagnostic value in RS virus infected small infants
86. Acute bronchiolitis in children
87. Effect of salbutamol on respiratory mechanics in bronchiolitis
88. Detection of respiratory syncytial virus in clinical specimens by viral culture, direct and indirect immunofluoresence and enzyme immunoassay
89. Ribavirin: is there a risk to hospital personnel?
90. Production of interferon in respiratory syncitial virus bronchiolitis
91. Cell mediated cytotoxic response to respiratory syncitial virus in infants with bronchiolitis
92. Ribavirin in respiratory syncytial virus infection. A double blind placebo controlled trial is needed
93. HLA class I antigens in severe RSV bronchiolitis
94. Ribavirin: adverse drug reactions, 1986–1988
95. An epidemiologic study of altered clinical reactivity to respiratory syncitial virus infection in children previously vaccinated with an inactivated RS virus vaccine
96. Appearance of complement components and immunoglobulins on nasopharyngeal epithelial cells following naturally acquired infection with respiratory syncitial virus
97. Respiratory syncitial virus (RSV) specific immune complexes in nasopharyngeal secretions after natural infection with RSV
98. Respiratory syncitial virus disease in infants despite prior administration of antigenic activated vaccine
99. Clinical and immunological response of infants and children to administration of low temperature adapted respiratory syncitial virus
100. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncitial virus (RSV) in infant and children
101. Epidemiology of respiratory syncitial virus infection in Washington DC. 1. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection
102. Cell mediated immunity to respiratory syncitial virus induced by inactivated vaccine or by infection
103. Pathogenesis of naturally acquired bovine respiratory syncitial virus in calves: morphological and serologic findings
104. Pathogenesis of naturally acquired bovine respiratory syncitial virus in calves: Evidence for the involvement of complement and mast cell mediators
105. Respiratory virus infection of peripheral blood monocytes correlation with ageing of cells and interferon production in-vitro
106. Antibody mediated enhancement of respiratory syncitial virus infection in two monocyte/macrophage cell lines
107. Respiratory failure and mechanical ventilation in severe bronchiolitis
108. Prevention of nosocomial respiratory syncitial virus infections through compliance with glove and gown isolation precautions
109. Corticosteroid treatment in bronchiolitis. A controlled collaborative study in 272 infants and children
110. Reduced IFNγ mRNA production in human neonates
111. Respiratory syncytial viral infection in infants with congenital heart disease
112. HIV envelope glycoprotein, antigen specific T-cell responses, and soluable CD4
113. Epidemiology of respiratory viral infection among paediatric inpatients over a six year period in North East England
114. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants
115. Interleukin-1 inhibitor production by human mononuclear leukocytes and leukocyte subpopulations exposed to respiratory syncitial virus
116. Interferon in nasal secretions from infants with viral respiratory tract infections
117. Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncitial virus
118. The association of viral and bacterial respiratory infections with exacerbation of wheezing in young asthmatic children
119. Cell free and cell bound antibody in nasal secretions from infants with respiratory syncitial virus infection
120. Prediction of the duration of hospitilization in patients with respiratory syncitial virus infection: use of clinical parameters
121. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects: quantification and comparison with immunoglobulins A and E
122. Respiratory syncitial virus infection of human cord and adult blood monocytes and alveolar macrophages
123. Experimental respiratory syncitial virus infection of adults
124. Acute bronchiolitis in infancy: treatment and prognosis
125. Fatal respiratory syncitial virus infection in severe combined immunodeficiency syndrome
126. Dissociated production of 1L-2 and IFNγ by PHA-stimulated lymphocytes in healthy infants
127. The role of the interferon system in respiratory syncitial virus infection
128. Ig Subclasses: Development of the serum concentrations in “normal” infants and children
129. Recovery of cytopathogenic agent from chimpanzees with coryza
130. Two distinct subtypes of human respiratory syncitial virus
131. Subgroup characteristics of respiratory syncitial virus strains recovered from children with two consecutive infections
132. Seasonal pattern of respiratory viral infection in children
133. Serum and nasal wash immunoglobulin G and A antibody response of infants and children to respiratory syncitial virus F and G glycoproteins following primary infections
134. Dissociation between serum neutralising and glycoprotein antibody responses of infants and children who received inactivated respiratory syncitial virus vaccine
135. Effect of age and pre existing antibody or serum antibody response of infants and children to the F and G glycoproteins during respiratory syncitial virus infection
136. Passive transfer of respiratory syncitial virus antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses
137. Receptors for human IgG subclasses on human alveolar macrophages
138. Respiratory syncitial virus infection of the newborn
139. Maternal antibody and respiratory syncitial virus infection in infancy
140. Management of respiratory failure in infants with acute viral bronchiolitis
141. IgG subclasses in infancy and childhood
142. Epidemiology of respiratory syncitial virus infections in Washington DC. II. Infection and disease with respect to age, immunological status, race and sex
143. Molecular mechanisms of action of ribavirin
144. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons g and a and prostaglandin E2
145. IgE production by alloreactive T-cell clones is mediated by II-4 and suppressed by IFN-γ
146. Sympathomimetic drugs in acute viral bronchiolitis. Their effect on pulmonary resistance
147. Characterisation of prolonged apnoeic episodes associated with respiratory syncitial virus infection
148. Acute fatal pneumonia in calves due to respiratory syncitial virus
149. Mast cell lines produce lymphokines in response to cross linkage of FceR1 or to calcium ionophores
150. Immunoglobulin E in bronchiolitis
151. Pilot study of recombinant interferon Alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncitial virus
152. Enhancement of respiratory syncitial virus pulmonary pathology in cotton rats by intramuscular inoculation of formation inactivated virus
153. Interferon in lungs
154. Wheezing, asthma and pulmonary dysfunction 10 years after infection with respiratory syncitial virus in infancy
155. Ribavirin: ambivalence about an antiviral agent
156. Respiratory syncitial virus infection: admissions to hospital in industrial, urban and rural areas
157. Arterial blood gas tensions in acute disease of lower respiratory tract in infancy
158. The treatment of bronchiolitis
159. Different effects of influenza virus, respiratory syncitial virus and sendai virus on human lymphocytes and macrophages
160. Interleukin 1 and interleukin 1 inhibitor production by human macrophages exposed to influenza virus or respiratory syncitial virus
161. Aerosolized ribavarin in the treatment of patients with respiratory syncytial virus disease
162. Pathogenesis of respiratory syncitial virus disease in infancy
163. Effect of bronchodilators on respiratory resistance in infants and young children with bronchiolitis and wheezy bronchitis
164. Interaction of paramyxoviruses with human basophils and their effect on histamine release
165. Respiratory virus envelope glycoprotein (G) has a novel structure
166. IgG subclasses in normal children
167. Cell mediated immunity in respiratory syncitial virus disease
168. State of the art. Macrophages and polymorphonuclear neutrophils in lung defense and injury
169. Study of 8 year old children with a history of respiratory syncitial virus bronchiolitis in infancy
170. Atropy does not predispose to RSV bronchiolitis or post bronchiolitic wheezing
171. Increases in plasma concentrations of a prostaglandin metabolite in acute airway obstruction
172. Childhood asthma following hospitaliation with acute viral bronchiolitis in infancy
173. Activation of complement by cells infected with respiratory syncitial virus
174. Biological activities of immunoglobulins of different classes and subclasses
175. Detection of IgE antibodies to bovine respiratory syncitial virus
176. Role of IgE in the pathogenesis of bovine respiratory syncitial virus in sequential infections in vaccinated and nonvaccinated calves
177. Human respiratory syncitial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge
178. Immune and histopathological response in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncitial virus
179. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants
180. Impaired production of IFNγ by newborn cells in-vitro is due to a functionally immature macrophage
181. Monoclonal antibodies protect against respiratory syncitial virus
182. Comparative virulence of respiratory syncitial virus subgroups A and B
183. Interferon alpha infections virus, and virus antigen secretion in respiratory syncitial virus infections of graded severity
184. Respiratory syncitial virus and the infants immune response
185. IgG and IgM antibodies to viral glycoproteins in respiratory syncitial virus infections of graded severity
186. The role of neutrophiles in the pathogenesis of rhinovirus infections
187. Respiratory syncitial virus infections in adults
188. The release of leukotrienes in the respiratory tract during infection with respiratory syncitial virus: role in obstructive airway disease
189. Serum immunoglobulin G antibody subclass responses to respiratory syncitial virus F and G glycoproteins after primary infections
190. Differential immunoglobulin G subclass antibody titers to respiratory syncitial virus F and G glycoproteins in adults
191. Defective IFNg production in the human neonate. II. Role of increased sensitivity to prostaglandin E
192. In re ribavirin: a case of premature adjudication?
193. Protection from respiratory syncitial virus infection in cotton rats by passive transfer of monoclonal antibodies
194. Antibody to respiratory syncitial virus polypeptides and their significance in human infection
195. Age related IgG subclass response to respiratory syncitial fusion protein in infected infants
196. Continuing respiratory problems three and a half years after acute viral bronchiolitis
197. Chest physiotherapy in acute bronchiolitis
198. The appearance of cell-bound IgE in respiratory tract epithelium after respiratory syncitial virus infection
199. The antibody response to primary and secondary infection with respiratory syncitial virus: kinetics of class specific responses
200. The development of respiratory syncitial virus-specific IgG and the release of histamine in nasopharyngeal secretions after infection
201. Defective regulations of immune responses in respiratory syncitial virus infections
202. Respiratory syncitial virus-specific antibody responses in immunoglobulin A and E isotypes to the F and G proteins and to intact virus after natural infection
203. Respiratory syncitial virus specific IgE responses following infection: evidence for a predominantly mucosal response
204. Predictive valve of respiratory syncitial virus—specific IgE responses for recurrent wheezing following bronchiolitis
205. Nucleotide sequence of the G protein gene of humanrespiratory syncitial virus reveals an unusual type of viral membrane protein
206. Viral receptors of the immunoglobulin superfamily
207. Decreased production of IFNγ by human neonatal cells. Instrinsic and regulatory deficiencies